ArticleBMC cancer2025
Preparing for allogeneic hematopoietic stem cell transplant: a multidisciplinary prehabilitation intervention is safe, feasible and demonstrates preliminary efficacy in acute myeloid leukemia and myelodysplastic syndromes.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundA multidisciplinary prehabilitation approach may help to counter the negative physical, psychological and social impacts experienced during an allogeneic hematopoietic stem cell transplant (allo-HSCT) among Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS) patients. Objective: This study investigated the feasibility, safety and preliminary efficacy of multidisciplinary prehabilitation in adults offered allo-HSCT.
methodsThis single-group pilot study recruited patients (≥ 18 years) with AML or MDS scheduled for allo-HSCT between June 2023 and July 2024. The intervention integrated exercise physiology, physiotherapy, dietetics, occupational therapy, psychology, and social work. Feasibility outcomes included uptake, retention, adherence, and acceptability. Safety was evaluated by monitoring adverse events. Preliminary efficacy was assessed across functional (30-s sit-to-stand, grip strength, 2-min step test, Timed Up and Go), nutritional (PG-SGA), and patient-reported outcomes (EORTC QLQ-C30, HADS, NCCN Distress Thermometer).
resultsOf 27 patients approached, 19 (70.4%) enrolled; one withdrew due to medical deterioration. Eleven participants completed the full 8 weeks, and seven completed 3–7 weeks before transplant. Adherence was high (79.3%), and acceptability was positive across disciplines. No deaths or serious (grade ≥ 3) adverse events occurred. Four intervention-related adverse events were observed (three mild, one moderate), and 34 sessions were cancelled for safety reasons (haemodynamic abnormalities or cytopenias). Preliminary efficacy analyses showed moderate effect size improvements in lower body strength (sit-to-stand, d = 0.49), mobility (Timed Up and Go, d = 0.63), aerobic capacity (2-min step test, d = 0.60), and nutritional status (PG-SGA, d = 0.41). Small-to-moderate effects were observed for several QOL domains, with improvements in constipation but increases in nausea, dyspnoea, and financial concerns.
conclusionBased on this study’s favourable safety, feasibility and preliminary efficacy results, future, larger-scale research is warranted to evaluate the efficacy of multidisciplinary prehabilitation more rigorously in this setting. The preliminary efficacy results provided by this study may be helpful to inform sample size calculations.
trial registrationThe trial was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) on 17 January 2023 (ID: ACTRN12623000052639).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.